The Cell Therapy Catapult at Guy’s Hospital, London has awarded a manufacturing contract to specialist cell therapy company Cellular Therapeutics.
The contract is designed to accelerate the Catapult’s clinical programme to develop an engineered T cell treatment for blood cancers such as acute myeloid leukaemia and myelodysplastic syndrome.
“We were impressed by Professor Robert Hawkins and the team at Cellular Therapeutics
Catapult CEO Keith Thompson
The contract will run for the next two to three years, supporting the current Phase I and II trials that involve the genetic modification of the patient’s own T cells, so that they may recognise and destroy WT1-expressing cancer cells when infused back into the body.
“We were looking for a company with the depth of expertise needed to manufacture a novel immune cell therapy and we were impressed by Professor Robert Hawkins and the team at Cellular Therapeutics,” said Keith Thompson, chief executive officer of the Cell Therapy Catapult.